At Selexis, diversity, inclusion, and equality have been a part of our DNA since our founding. Having varied perspectives drives innovation, impacts our products and services, and helps us better serve our partners and employees. While we have more work to do to advance diversity and inclusion, we are constantly growing, learning, and iterating to move our company forward.
Recent posts by Selexis admin
1 min read
Selexis Diversity Snapshot
December 14, 2022
1 min read
Selexis Corporate Overview
October 11, 2022
Selexis SA, a JSR Life Science Company, is the global leader in mammalian cell line development with best-in-class modular technology and highly specialized solutions that enable the life science industry to rapidly develop and commercialize innovative biotherapeutics and vaccines.
1 min read
Selexis Capabilities
October 11, 2022
For over 20 years, Selexis has helped its partners to predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology PlatformTM is being used by global partners as one of the most robust CLD technologies worldwide.
1 min read
JSR Life Sciences, KBI Biopharma, Selexis Overview
July 27, 2022
USING INNOVATION TO DE-RISK AND ACCELERATE THE DISCOVERY AND DEVELOPMENT OF NEW THERAPEUTICS
JSR Life Sciences brings together the best-in-class capabilities of its affiliates, deep biochemical knowledge and understanding of human disease biology, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for its customers.
Keywords: KBI Biopharma JSR Life Sciences Gene to GMP Selexis Contract Development Manufacturing Organization CDMO CMO cell line
1 min read
Selexis Customer Survey Results
June 16, 2022
In 2022, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.
1 min read
Selexis Rescue Promising Programs
June 22, 2021
Solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bispecific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a range of production and secretion challenges such as ensuring appropriate folding and subunit pairing.
